CA2963952C - Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'etats pathologiques - Google Patents

Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'etats pathologiques Download PDF

Info

Publication number
CA2963952C
CA2963952C CA2963952A CA2963952A CA2963952C CA 2963952 C CA2963952 C CA 2963952C CA 2963952 A CA2963952 A CA 2963952A CA 2963952 A CA2963952 A CA 2963952A CA 2963952 C CA2963952 C CA 2963952C
Authority
CA
Canada
Prior art keywords
fatty acid
omega
acid
disease
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2963952A
Other languages
English (en)
Other versions
CA2963952A1 (fr
Inventor
Frederick D. Sancilio
Thorsteinn Thorsteinsson
Glynis DANIEL-ARCHIBALD
Miguel LOPEZ-TOLEDANO
Ahmed Abd Almalik Ahmed Mohammed DAAK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generx Inc
Original Assignee
Generx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54347886&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2963952(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Generx Inc filed Critical Generx Inc
Publication of CA2963952A1 publication Critical patent/CA2963952A1/fr
Application granted granted Critical
Publication of CA2963952C publication Critical patent/CA2963952C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne des compositions contenant au moins un acide gras oméga 3 (sous la forme de triglycéride, d'ester ou d'ester d'acide gras libre) et au moins un agent tensioactif ; les compositions formant des micelles lorsqu'elles sont en contact avec un milieu aqueux. L'invention concerne également des méthodes d'administration à un patient d'une composition contenant au moins un acide gras oméga 3 (sous la forme de triglycéride, d'ester ou d'ester d'acide gras libre) et au moins un agent tensioactif, les compositions formant des micelles lorsqu'elles sont en contact avec un milieu aqueux, la biodisponibilité de l'acide gras oméga 3 étant sensiblement indépendante d'un effet alimentaire. Les compositions selon l'invention sont utiles dans le traitement de certains états pathologiques pouvant comprendre les syndromes de malabsorption (1), la cholangite sclérosante primitive (CSP) (2), la stéatose hépatique non alcoolique (SHNA) (3), la drépanocytose (4), la dégénérescence maculaire liée à l'âge (DMLA) (5) et les maladies neurodégénératives (6), notamment la maladie de Parkinson (MP), la maladie d'Alzheimer (MA), la sclérose latérale amyotrophique (SLA ou maladie de Lou Gehrig), l'épilepsie, le syndrome bipolaire, les lésions cérébrales traumatiques, la neuropathie périphérique et la sclérose en plaques (SP). L'invention concerne également diverses formes galéniques pour l'administration des compositions, ainsi que l'utilisation de ces compositions dans des aliments fonctionnels. L'invention concerne encore des kits contenant des instructions d'administration de ces compositions.
CA2963952A 2014-10-10 2015-10-09 Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'etats pathologiques Active CA2963952C (fr)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201462062646P 2014-10-10 2014-10-10
US201462062634P 2014-10-10 2014-10-10
US201462062652P 2014-10-10 2014-10-10
US201462062638P 2014-10-10 2014-10-10
US201462062651P 2014-10-10 2014-10-10
US201462062643P 2014-10-10 2014-10-10
US62/062,652 2014-10-10
US62/062,638 2014-10-10
US62/062,634 2014-10-10
US62/062,651 2014-10-10
US62/062,646 2014-10-10
US62/062,643 2014-10-10
PCT/US2015/054933 WO2016057915A1 (fr) 2014-10-10 2015-10-09 Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques

Publications (2)

Publication Number Publication Date
CA2963952A1 CA2963952A1 (fr) 2016-04-14
CA2963952C true CA2963952C (fr) 2023-10-17

Family

ID=54347886

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2963952A Active CA2963952C (fr) 2014-10-10 2015-10-09 Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'etats pathologiques

Country Status (8)

Country Link
EP (1) EP3212236A1 (fr)
BR (1) BR112017007428A2 (fr)
CA (1) CA2963952C (fr)
CL (1) CL2017000867A1 (fr)
MA (1) MA40846A (fr)
MX (2) MX2017004324A (fr)
WO (1) WO2016057915A1 (fr)
ZA (1) ZA201702385B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017193563A1 (fr) * 2015-11-13 2017-11-16 深圳君圣泰生物技术有限公司 Composition, et application et préparation pharmaceutique de cette dernière
CN116492339A (zh) * 2015-11-13 2023-07-28 深圳君圣泰生物技术有限公司 一种组合物及其用途、药物制剂
US11241408B2 (en) 2016-08-12 2022-02-08 Pharmako Biotechnologies Pty Limited Omega-3 compositions and methods relating thereto
FR3092968B1 (fr) * 2019-02-22 2021-05-21 Microphyt Complement alimentaire
IT201900007202A1 (it) * 2019-05-24 2020-11-24 Pavia Farm S R L Composizione a base di vitamine liposolubili ad elevato assorbimento enterico
MX2022001238A (es) 2019-08-13 2022-07-13 Team Foods Colombia Sa Composicion lipidica que comprende antioxidantes y polifenoles naturales como alternativa no farmacologica para el tratamiento y la prevencion de nafld.
CN115737555B (zh) * 2022-05-20 2024-06-21 深圳海王医药科技研究院有限公司 一种千金藤素自微乳组合物、制剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2972063C (fr) * 2009-05-22 2019-12-17 Mochida Pharmaceutical Co., Ltd. Composition auto-emulsifiante d'acide gras .omega.3
AR082930A1 (es) * 2010-09-08 2013-01-16 Pronova Biopharma Norge As Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina
EP2793867B1 (fr) * 2011-12-22 2021-01-20 Baes, Erik Capsules à libération retardée de gélatine/alginate comprenant des acides gras oméga-3, et leurs procédés et leurs utilisations
MY189576A (en) * 2012-03-30 2022-02-17 Micelle Biopharma Inc Omega-3 fatty acid ester compositions

Also Published As

Publication number Publication date
EP3212236A1 (fr) 2017-09-06
MX2017004324A (es) 2017-07-04
CA2963952A1 (fr) 2016-04-14
WO2016057915A1 (fr) 2016-04-14
CL2017000867A1 (es) 2017-11-03
MX2020002238A (es) 2020-07-13
MA40846A (fr) 2017-09-05
ZA201702385B (en) 2020-12-23
BR112017007428A2 (pt) 2017-12-19

Similar Documents

Publication Publication Date Title
CA2963952C (fr) Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'etats pathologiques
JP6682596B2 (ja) ω３脂肪酸の自己乳化組成物
JP6722118B2 (ja) ω３脂肪酸の自己乳化組成物
CN102088978B (zh) 血脂异常症的改善或治疗药
US9302016B2 (en) Omega-3 fatty acid ester compositions
US20210322360A1 (en) Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
AU2016324349A1 (en) Ubiquinone and ubiquinol compositions, and methods relating thereto
JP2011006380A (ja) ω３脂肪酸の乳化組成物
US20200330422A1 (en) Formulations for Treating and/or Preventing Disease
US20160296492A1 (en) Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
US20160228398A1 (en) Omega-3 fatty acid ester compositions
US20210324302A1 (en) Omega-3 fatty acid ester compositions
US20160235853A1 (en) Omega-3 fatty acid ester compositions
US20150125529A1 (en) Omega-3 Fatty Acid Ester Compositions
US20150125530A1 (en) Omega-3 Fatty Acid Ester Compositions
US20150132389A1 (en) Omega-3 Fatty Acid Ester Compositions
TW201938143A (zh) ω３脂肪酸之自體乳化劑及自體乳化組成物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201008

EEER Examination request

Effective date: 20201008

EEER Examination request

Effective date: 20201008

EEER Examination request

Effective date: 20201008

EEER Examination request

Effective date: 20201008

EEER Examination request

Effective date: 20201008

EEER Examination request

Effective date: 20201008

EEER Examination request

Effective date: 20201008

EEER Examination request

Effective date: 20201008